AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Jul 3, 2025
30849_dirs_2025-07-03_9eb87476-48b2-4cc9-a065-20ab481f56cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-07-01
Reporting Person: Garfield Alastair (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-07-01 | Common Stock | M | 4445 | — | Acquired | 4445 | Direct |
| 2025-07-02 | Common Stock | S | 1313 | $64.81 | Disposed | 3132 | Direct |
| 2025-07-02 | Common Stock | S | 6 | $64.60 | Disposed | 3126 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-07-01 | Restricted Stock Units | $ | M | 4445 | Disposed | Common Stock (4445) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.